Jennifer Cook Sells 148,589 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 148,589 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the transaction, the director directly owned 8,383 shares of the company’s stock, valued at $742,230.82. The trade was a 94.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Trading Up 1.2%

Shares of NASDAQ:BBIO opened at $84.09 on Wednesday. The firm’s 50 day moving average is $70.31 and its two-hundred day moving average is $72.18. BridgeBio Pharma, Inc. has a 52 week low of $42.09 and a 52 week high of $93.42. The firm has a market capitalization of $16.47 billion, a P/E ratio of -22.48 and a beta of 0.95.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the previous year, the business posted ($0.88) earnings per share. The company’s revenue was up 66.8% on a year-over-year basis. Analysts predict that BridgeBio Pharma, Inc. will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BBIO. Brooklands Fund Management Ltd acquired a new stake in shares of BridgeBio Pharma during the 4th quarter valued at $210,348,000. Price T Rowe Associates Inc. MD grew its holdings in shares of BridgeBio Pharma by 144.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after acquiring an additional 2,261,181 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of BridgeBio Pharma by 25.8% in the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after acquiring an additional 2,259,378 shares during the last quarter. Norges Bank acquired a new stake in shares of BridgeBio Pharma during the fourth quarter worth $116,802,000. Finally, Wellington Management Group LLP raised its position in shares of BridgeBio Pharma by 130.4% during the fourth quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock worth $179,654,000 after purchasing an additional 1,329,537 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BBIO shares. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Royal Bank Of Canada started coverage on shares of BridgeBio Pharma in a research note on Thursday, April 9th. They set an “outperform” rating and a $100.00 price objective on the stock. Mizuho reduced their price objective on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Truist Financial upped their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Finally, Raymond James Financial lowered shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright lifted its earnings estimates for BridgeBio Pharma across multiple future periods, including FY2027 EPS to $2.19 from $2.12, while reiterating a Buy rating and a $120 price target. HC Wainwright raises BridgeBio Pharma price target to $120
• Positive Sentiment: HC Wainwright also raised its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 earnings estimates, reinforcing the view that BridgeBio’s earnings trajectory is improving. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: RBC Capital reaffirmed its Buy view on BridgeBio Pharma, adding to the overall positive analyst backdrop. RBC Capital reaffirms buy rating on BridgeBio Pharma
• Neutral Sentiment: A recent article noted BridgeBio could be a relative beneficiary after a competing biotech trial miss, which may have helped sentiment around the sector and the stock. Phase 3 failure sends biotech winners and losers in opposite directions
• Negative Sentiment: Director Andrea Ellis sold 17,167 shares, and another filing shows Director Jennifer E. Cook sold 148,589 shares, which can weigh on investor sentiment even though both trades were made under pre-arranged 10b5-1 plans. Insider selling at BridgeBio Pharma

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.